| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Biogen's tau therapy drives bigger benefits in 2-year Alzheimer's update | ||
| Mi | Less than a year into the job, Everett Cunningham steps down as Quanterix CEO | ||
| Mi | Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China's Starna | ||
| Mi | Clene Nanomedicine uses CRO Veristat's biostatistics platform for FDA submission | ||
| Mi | Vertex signs $220M deal with Genomics to re-up long-running discovery pact | ||
| Mi | At Fierce's London event, Big Pharmas tell biotechs to 'be transparent' to secure deals | ||
| Mi | Priavoid's Alzheimer's pill fails to prove efficacy in phase 2 trial | ||
| Mi | Merck axes $2.7B BTK inhibitor program after seeing phase 3 data | ||
| Mi | FDA clears MiniMed Fit tubeless insulin pump | ||
| Mi | Cognito phase 3 flops in light-and-sound Alzheimer's trial, but sees 'signal' for HOPE | ||
| Di | Scientists uncover 'very detailed map' of an enzyme target for rare metabolic disease | ||
| Di | Kyntra axes mid-stage ADC, adding to years of stumbles | ||
| Di | Medtronic pays $380M-plus for Contego Medical buyout | ||
| Di | Isomorphic Labs raises $5B series C months after $2.1B round | ||
| Di | Why 2027 could be 'Europe's year to shine': Panelists debate biotech funding at Fierce's London event | ||
| Di | Marrow extracts $120M series B to advance preclinical blood disease therapy | ||
| Di | Sellas marks 9-month survival benefit in late-stage leukemia vaccine study | ||
| Di | Lilly signs $5.9B deal with Stipple to unlock oncology targets | ||
| Mo | Helus' chemically modified psychedelic hits key goals in phase 3 depression trial | ||
| Mo | Biogen inks $411M neurodegeneration pact with protein degrader biotech TrimTech | ||
| Mo | Lilly secures another myelofibrosis option via $1.5B deal for JPM-founded Calytrix | ||
| Mo | J&J pays $2.2B upfront for Ollin to challenge Roche's Vabysmo with phase 3 bispecific | ||
| Mo | Building resilient biomanufacturing supply networks | ||
| Mo | Aclaris scratches TSLP program from pipeline after flunking phase 2 eczema test | ||
| Mo | Flagship commits £100M to set up AI-focused biotech incubation outpost in London |